Provided herein are compositions comprising ixabepilone, or a pharmaceutically acceptable salt thereof, and a copolymer represented by formula I: ##STR00001##
Also provided are methods of treating cancer using the compositions described herein, and methods of preparing the compositions.

The application describes treatment of hepatic encephalopathy using gastrointestinal specific antibiotics. One example of a gastrointestinal specific antibiotic is rifaximin.

The application describes treatment of hepatic encephalopathy using gastrointestinal specific antibiotics. One example of a gastrointestinal specific antibiotic is rifaximin.

The application describes treatment of hepatic encephalopathy using gastrointestinal specific antibiotics. One example of a gastrointestinal specific antibiotic is rifaximin.

The present disclosure provides a pH-sensitive membranolytic polymer material and a preparation method and application thereof. The pH-sensitive membranolytic polymer material has the structure shown in Formula (I). At normal physiological pH, the polymer material is hydrophobic neutral, and can be self-assembled into PEG coated nanoparticles with weak interaction with cell membrane; when the pH decreases, the polymer material can be protonated to form an amphiphilic structure consisting of hydrophobic domain and cationic domain, which has strong interaction with the cell membrane and strong membranolytic activity, so the polymer material can kill tumor cells or bacteria efficiently and selectively.

##STR00001##

Provided are compounds that may function as functionalized polymerization initiators, for instance in the manufacture of ophthalmic lenses, and to methods of such manufacture. The compounds are of formula I:

##STR00001##

wherein R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5, T, p, q, and n are as defined herein.

Provided are compounds that may function as functionalized polymerization initiators, for instance in the manufacture of ophthalmic lenses, and to methods of such manufacture. The compounds are of formula I:

##STR00001##

wherein R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5, T, p, q, and n are as defined herein.

The present invention relates, in general, to pattern-recognition receptors (PRRs), including toll-like receptors (TLRs), and, in particular, to a method of inhibiting nucleic acid-induced activation of, for example, endosomal TLRs using an agent that binds to the nucleic acid (“nucleic acid binding agent”), preferably, in a manner that is independent of the nucleotide sequence, the chemistry (e.g., DNA or RNA, with or without base or sugar modifications) and/or the structure (e.g., double-stranded or single-stranded, complexed or uncomplexed with, for example protein) of the nucleic acid(s) responsible for inducing TLR activation. The invention also relates to methods of identifying nucleic acid binding agents suitable for use in such methods.

The present invention relates, in general, to pattern-recognition receptors (PRRs), including toll-like receptors (TLRs), and, in particular, to a method of inhibiting nucleic acid-induced activation of, for example, endosomal TLRs using an agent that binds to the nucleic acid (“nucleic acid binding agent”), preferably, in a manner that is independent of the nucleotide sequence, the chemistry (e.g., DNA or RNA, with or without base or sugar modifications) and/or the structure (e.g., double-stranded or single-stranded, complexed or uncomplexed with, for example protein) of the nucleic acid(s) responsible for inducing TLR activation. The invention also relates to methods of identifying nucleic acid binding agents suitable for use in such methods.

The present invention relates to the amelioration of toxic effects that are caused by therapies aimed at FGFR4-inhibition. In particular, the invention relates to the combination of FGFR4 inhibitors and agents capable of reducing bile acid levels and to the use thereof in the treatment of diseases.